Medtronic PLC (NYSE:MDT) Stock Has Consensus Price Target of $102.92 According to Brokerages

Posted by Geri Gentry on Oct 13th, 2026

Medtronic PLC (NYSE:MDT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-eight analysts that are presently covering the stock, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and eighteen have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $102.88.

Several research analysts have recently weighed in on MDT shares. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $92.00 price objective on shares of Medtronic in a research report on Thursday, September 3rd. Stifel Nicolaus raised their target price on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a report on Wednesday, September 2nd. TD Cowen restated a “buy” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday, September 30th. Finally, Robert W. Baird lifted their target price on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd.

View Our Latest Stock Analysis on Medtronic

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.27% of the stock is owned by insiders.

Institutional Trading of Medtronic

A number of hedge funds have recently bought and sold shares of MDT. HF Advisory Group LLC lifted its holdings in Medtronic by 5.2% in the third quarter. HF Advisory Group LLC now owns 23,577 shares of the medical technology company’s stock valued at $2,034,000 after acquiring an additional 1,165 shares during the period. Valley Wealth Managers Inc. boosted its position in Medtronic by 3.1% in the third quarter. Valley Wealth Managers Inc. now owns 54,193 shares of the medical technology company’s stock worth $4,676,000 after purchasing an additional 1,631 shares during the last quarter. Atlas Brown Inc. boosted its position in Medtronic by 5.5% in the third quarter. Atlas Brown Inc. now owns 2,758 shares of the medical technology company’s stock worth $238,000 after purchasing an additional 145 shares during the last quarter. GK Wealth Management LLC purchased a new position in Medtronic in the third quarter worth about $162,000. Finally, Decker Wealth Management LLC grew its stake in shares of Medtronic by 2.9% during the 3rd quarter. Decker Wealth Management LLC now owns 44,307 shares of the medical technology company’s stock valued at $3,823,000 after purchasing an additional 1,231 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

NYSE MDT opened at $91.61 on Friday. Medtronic has a one year low of $73.31 and a one year high of $106.33. The stock has a 50-day moving average of $90.38 and a 200 day moving average of $84.80. The company has a market capitalization of $117.18 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 2.02 and a beta of 0.55. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.

Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts forecast that Medtronic will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said its exchange offer for MiniMed Group shares was oversubscribed. The company plans to exchange all of its remaining 252.8 million MiniMed shares for outstanding Medtronic ordinary shares, completing the disposition of its remaining MiniMed stake. The transaction may simplify Medtronic’s portfolio and reduce exposure to the slower-growth diabetes business. Medtronic Announces Preliminary Results of MiniMed Group Exchange Offer
Positive Sentiment: An investment commentary argued that Medtronic’s underperformance over the past year has left the stock at a modest valuation while its growth outlook is improving. This supports the view that the shares may offer value if operating momentum continues. Medtronic’s Modest Valuation Meets an Improving Growth Outlook
Neutral Sentiment: BTIG Research lowered its price target to $99 from $100 but maintained a Buy rating, implying continued upside based on its valuation assessment. The reduced target is a modest negative, while the retained Buy rating is supportive. Medtronic Price Target Cut by BTIG Research
Neutral Sentiment: Jim Cramer expressed a favorable view of Medtronic but criticized MiniMed, reinforcing the market’s potential preference for Medtronic after the separation. However, the comments are opinion-based and are unlikely to materially affect fundamentals. Jim Cramer’s Views on MiniMed and Medtronic

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.